X0306 4 2020-10-01 0 0001697532 Applied Therapeutics Inc. APLT 0001775394 Funtleyder Leslie D. C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 NEW YORK NY 10017 1 0 0 0 Common Stock 2020-10-01 4 M 0 30000 4.70 D 47148 D Common Stock 2020-10-01 4 S 0 22671 20.03 D 24477 D Common Stock 2020-10-01 4 S 0 1353 20.75 D 23124 D Common Stock 2020-10-02 4 S 0 5976 20.07 D 17148 D Stock Option (Right to Buy) 4.70 2020-10-01 4 M 0 30000 0.00 D 2029-03-06 Common Stock 30000 40502 D Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Sales made pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.5100 to $20.5000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Weighted average price. These shares were sold in multiple transactions at prices ranging from $20.5100 to $21.1000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6500 to $20.5600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. These options became fully vested on May 28, 2019. /s/ Shoshana Shendelman as attorney-in-fact 2020-10-05